Shots:
- Roche has received CE Mark for Elecsys pTau217 to measure the phosphorylated Tau (pTau) 217 protein to help rule in or rule out Alzheimer’s-related amyloid pathology
- CE Mark was backed by retrospective real-world studies in early-stage Alzheimer’s pts, incl. Subjective Cognitive Decline, Mild Cognitive Impairment, & Mild Dementia, where individuals experience memory changes but largely maintain independent living
- Elecsys pTau217, developed in collaboration with Eli Lilly, is the first single-assay blood test designed to be used across primary & secondary care settings, offering a faster, minimally invasive diagnostic alternative with accuracy comparable to spinal fluid testing against PET-CT scans
Ref: Globenewswire | Image: Roche | Press Release
Related News: Roche Receives CE Mark for its Elecsys ApoE4 Test to Support Blood-Based Alzheimer’s Biomarker Testing
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
